Study population:

Patients with heart failure  Patients had NYHA Class IV heart failure in the 6 months prior to enrolment, but were NYHA class III or IV at enrolment.

Comments:

The mean age of patients was 65 years.

Spironolactone also reduced the frequency of hospitalisation for heart failure and produced a significant improvement in the symptoms of heart failure.

Patients in the trial were on an ACE inhibitor (if tolerated) and a diuretic.  10% of patients were also on a beta-blocker.

 

Outcome Duration NNT Annualised NNT
Prevent one death (all cause) 24 months (mean duration of followup)

9

18

References

Pitt B, Zannad F, Remme W, Cody R, Castaigne W et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. The New England Journal of Medicine. 1999; 341(10): 709-717